Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Cellectar Biosciences, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Mar 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Cellectar Biosciences, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. CLR 125 appears in 2 tracked Cross-Sector stories from March 5, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CLR 125. Shared-story counts are live from our verified record — not editorial picks.
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
Financial Results
Company reports 2025 results and provides corporate update.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Source: The Manila Times · Benzinga
